2. Signaling Pathways
  3. Anti-infection
  4. HIV

HIV

Human immunodeficiency virus

HIV

Related Products

PDF 1.67 MB

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

HIV Isoform Specific Products:

HIV Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109056R
    Elsulfavirine (Standard)
    		Inhibitor
    Elsulfavirine (Standard) is the analytical standard of Elsulfavirine (HY-109056). This product is intended for research and analytical applications. Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer.
    Elsulfavirine (Standard)
  • HY-120157
    Vif-ElonginC interaction inhibitor 1
    		Inhibitor
    Vif-ElonginC interaction inhibitor 1 (compound VEC-5) is a potent Vif inhibitor. Vif-ElonginC interaction inhibitor 1 can restrict HIV-1 in Vif-nonpermissive cells. Vif-ElonginC interaction inhibitor 1 can protect A3G, APOBEC3C (A3C), and APOBEC3F (A3F) from Vif-mediated degradation and drastically inhibit Vif function through blocking the interaction between Vif and ElonginC. Vif-ElonginC interaction inhibitor 1 enhances A3G incorporation into HIV-1 virions to reduce viral infectivity.
    Vif-ElonginC interaction inhibitor 1
  • HY-117477
    DPC 963
    		Inhibitor
    DPC-963 is an oral active non-nucleoside reverse transcriptase inhibitor with the IC50 of 18 nM. DPC-963 can be used for study of HIV.
    DPC 963
  • HY-181090
    HIV-1-IN-92
    		Inhibitor
    HIV-1-IN-92 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase with an IC50 of 0.11 μM against HIV-1 reverse transcriptase. HIV-1-IN-92 exhibits activity against both wild-type HIV-1 IIIB and mutant HIV-1 strains. HIV-1-IN-92 can be used in research related to acquired immunodeficiency syndrome (AIDS).
    HIV-1-IN-92
  • HY-172408
    NNRT-IN-6
    		Inhibitor
    NNRT-IN-6 (Compound 13a) is the non-nucleoside reverse transcriptase inhibitor (NNRT) for HIV-1 reverse transcriptase (HIV-1 RT) with IC50 of 0.41 μM. NNRT-IN-6 inhibits HIV-1 wildtype and mutant strains L100I, K103N, Y181C, Y188L, E138K, F227L/V106A and RES056 with EC50 of 6.2-250 nM.
    NNRT-IN-6
  • HY-78726S2
    Fosamprenavir-13C6
    		Inhibitor
    Fosamprenavir-13C6 is the 13C-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection.
    Fosamprenavir-<sup>13</sup>C<sub>6</sub>
  • HY-180187
    019854-B06
    		Inhibitor
    019854-B06 is a potent inhibitor of Tat-mediated HIV-1 transcription (IC50 = 1.44 μM), exhibiting antiviral activity against HIV-1 (EC50 = 0.83 μM). 019854-B06 binds to Tat peptide (KD = 33.5 μM), but not to TAR RNA. 019854-B06 neither promotes Tat degradation nor disrupts the Tat/CycT1 complex, supporting a Tat-centric, nondegradative mechanism.
    019854-B06
  • HY-15440AS
    Fostemsavir-d8
    		Inhibitor
    Fostemsavir-d8 (BMS-663068-d8) is deuterium labeled Fostemsavir. Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.
    Fostemsavir-d<sub>8</sub>
  • HY-168525
    IC-1k
    IC-1k is a potent HIV-1 inhibitor with EC50 values of 2.69, 97.97 nM for HIV-1 IIIB, HIV-2 ROD, respectively. IC-1k shows cytotoxicity. IC-1k shows antiviral activity.
    IC-1k
  • HY-123896
    Calceolarioside A
    		Inhibitor
    Calceolarioside A is phenylethanoid glycoside with moderate binding affinity on HIV gp41.
    Calceolarioside A
  • HY-122018
    GS-9148
    		Inhibitor
    GS-9148 is a ribose-modified HIV-1 nucleotide reverse transcriptase (RT) inhibitor with an EC50 value of 10.6 µM. GS-9148 shows antiretroviral activity for K65R, L74V, or M184V RT mutation.
    GS-9148
  • HY-120630
    BMS-663749
    		Inhibitor
    BMS-663749 is an HIV attachment inhibitor and phosphonooxymethyl prodrug of BMS-488043 (HY-14135).
    BMS-663749
  • HY-125433
    A-75925
    A-75925 is a human immunodeficiency virus type 1 (HIV-1) proteinase inhibitor and can be utilized in HIV-1 rersearch.
    A-75925
  • HY-182566
    ITI-367
    		Inhibitor
    ITI-367 is a HIV-1 inhibitor that targets the nuclear localization signal 1 (NLS-1) of HIV-1 matrix protein and the interaction between HIV-1 pre-integration complex (PIC) and importin-β. ITI-367 inhibits HIV-1 replication at the pre-integration stage, reduces the formation of 2-LTR circles, and sequesters viral DNA in the cytoplasm. ITI-367 can be used for the research of HIV infection.
    ITI-367
  • HY-106634R
    Mitoguazone (Standard)
    		Inhibitor
    Mitoguazone (Standard) is the analytical standard of Mitoguazone. This product is intended for research and analytical applications. Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity. Mitoguazone is a brain-penetrant and competitive S-adenosyl-methionine decarboxylase (SAMDC) inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces cell apoptosis. Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma treatment.
    Mitoguazone (Standard)
  • HY-15971R
    AMD 3465 hexahydrobromide (Standard)
    		Inhibitor
    AMD 3465 (hexahydrobromide) (Standard) is the analytical standard of AMD 3465 (hexahydrobromide). This product is intended for research and analytical applications. AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
    AMD 3465 hexahydrobromide (Standard)
  • HY-173009
    PROTAC CG167
    		Inhibitor
    PROTAC CG167 is a selective and potent CypA PROTAC degrader. PROTAC CG167 degrades CypA in a dose-dependent manner (Jurkat: DC50: 123 nM). PROTAC CG167 can inhibit HIV-1 and HCV and exhibits antiviral activity. (Pink: CypA Ligand (HY-170997); Black: Linker (HY-W123015); Blue: E3 Ligase Ligand (HY-112078))
    PROTAC CG167
  • HY-N0858R
    Gomisin G (Standard)
    		Inhibitor
    Gomisin G (Standard) is the analytical standard of Gomisin G. This product is intended for research and analytical applications. Gomisin G is a lignin from S. chinesis with anti-HIV (EC50 = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers.
    Gomisin G (Standard)
  • HY-10522R
    LEDGIN6 (Standard)
    		Inhibitor
    LEDGIN6 (Standard) is the analytical standard of LEDGIN6 (HY-10522). This product is intended for research and analytical applications. LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase.
    LEDGIN6 (Standard)
  • HY-178985
    HIV-1-IN-90
    		Inhibitor
    HIV-1-IN-90 is a potent HIV inhibitor. HIV-1-IN-90 exhibits potent inhibitory activity against multiple drug-resistant HIV-1 strains with EC50s of 1.5-31 nM. HIV-1-IN-90 has good security. HIV-1-IN-90 can be used for research on HIV virus infection.
    HIV-1-IN-90
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
HIV Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.